Reimbursement and coverage risk
TearCare adoption depends on payor coverage and coding status.
- Scope
- Dry Eye segment
- Materiality
- high
Sight Sciences, Inc.
Sight Sciences, Inc. develops and commercializes interventional ophthalmic technologies used by eye care providers to treat glaucoma and dry eye disease. Its portfolio includes surgical devices for glaucoma procedures and the TearCare system for dry eye treatment, sold primarily in the United States with additional international distribution in select European markets.
−47,3 %
86,2 %
−49,7 %
−3,1 %
10.22
9.52
| % | |
|---|---|
| Surgical Glaucoma | 98% Interventional devices used by ophthalmic surgeons in glaucoma procedures, including OMNI and SION. |
| Dry Eye | 2% TearCare systems, SmartHubs, SmartLids, and related accessories for dry eye treatment. |
Sight Sciences sells primarily to eye care providers, including ophthalmologists, optometrists, ambulatory surgery...
- Ambulatory surgery centers and HOPDsprimary
Buy OMNI and SION for outpatient glaucoma procedures and value devices that fit procedural workflows.
- Ophthalmology practicesprimary
Purchase glaucoma devices and TearCare systems to expand treatment options for eye disease patients.
- Optometry practicessecondary
Buy TearCare for dry eye treatment and recurring SmartLid consumables.
- Third-party payorsprimary
Influence adoption through reimbursement and coverage decisions for TearCare and related procedures.
The company generates substantially all of its revenue in the United States, where its direct sales organization is...
- •Substantially all revenue is generated in the United States
- •Direct sales force is concentrated in the U.S. market
- •OMNI is sold through distributors in select European countries
- •Direct sales are maintained in Germany and the United Kingdom
- •European reimbursement and market access affect adoption
Sight Sciences is focused on expanding adoption of its interventional eye care technologies by building clinical...
01
Expand reimbursement for TearCareshort-term
Coverage decisions are central to patient access and adoption in dry eye.
02
Strengthen commercial executionshort-term
The products require specialized training and consultative selling to drive procedural adoption.
03
Broaden international marketsmedium-term
Geographic expansion can diversify revenue and extend the installed base.
04
Develop new interventional technologieslong-term
Pipeline innovation supports long-term relevance in glaucoma and ocular surface disease.
The business depends on reimbursement, physician adoption, and continued clinical differentiation in highly competitive...
Competitive pressure in MIGS and dry eye
Larger and better-capitalized rivals can offer alternative devices and procedures.
- Scope
- OMNI, SION, TearCare
- Materiality
- high
Third-party manufacturing and supply chain concentration
The company relies on external manufacturers and many components are single-source.
- Scope
- OMNI, SION, TearCare SmartLids
- Materiality
- high
Early-stage operating losses
The company expects continued losses while investing in commercialization and product development.
- Scope
- Enterprise-wide
- Materiality
- high
China sourcing and tariff exposure
A substantial portion of products and components are manufactured in China.
- Scope
- Imported components and finished goods
- Materiality
- high
Revenue recognition
Affects quarterly revenue mix and comparability
Stock-based compensation
Affects operating expense and net loss
Debt-related accounting
Affects interest expense and below-operating items
Seasonality
Affects quarterly revenue and margin comparability
: 29.4.2026